411 related articles for article (PubMed ID: 29685696)
1. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
3. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
4. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
5. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
[TBL] [Abstract][Full Text] [Related]
6. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
9. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
10. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
11. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
12. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis.
Han ZJ; Wu XD; Cheng JJ; Zhao SD; Gao MZ; Huang HY; Gu B; Ma P; Chen Y; Wang JH; Yang CJ; Yan ZH
PLoS One; 2015; 10(8):e0134376. PubMed ID: 26244664
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
18. Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?
Logan JK; Mentz RJ
Curr Heart Fail Rep; 2019 Dec; 16(6):250-256. PubMed ID: 31741230
[TBL] [Abstract][Full Text] [Related]
19. B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis.
De Vecchis R; Esposito C; Di Biase G; Ariano C; Giasi A; Cioppa C
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):122-34. PubMed ID: 24522083
[TBL] [Abstract][Full Text] [Related]
20. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials.
Li P; Luo Y; Chen YM
Heart Lung Circ; 2013 Oct; 22(10):852-60. PubMed ID: 23602555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
